Alnylam Pharmaceuticals, Inc. filed a Form 8-K on November 5, 2026, disclosing a $1.0 billion common stock repurchase program authorized by its Board of Directors on November 2, 2026, and announcing that Executive Vice President and Chief Commercialization Officer Tolga Tanguler will depart the company in December 2026.

Key Highlights

  • $1.0 billion repurchase program: The Board of Directors authorized a program to repurchase up to $1.0 billion of the company's common stock, effective November 2, 2026.
  • ~$500 million targeted by year-end: The company anticipates repurchasing approximately $500 million of its common stock under the program by the end of 2026, with the balance during 2027.
  • No expiration date: The 2026 Repurchase Program does not have an expiration date and does not obligate the company to repurchase any particular dollar amount or number of shares.
  • Program may be modified: The 2026 Repurchase Program may be modified, suspended, or discontinued at any time without prior notice.
  • Tanguler departure announced: Tolga Tanguler will depart from his role as Executive Vice President, Chief Commercialization Officer in December 2026.
  • Separation agreement pending: Mr. Tanguler and the company intend to enter into a written agreement no later than his separation date containing the terms of his departure.

Alnylam Pharmaceuticals Discloses $1B Stock Repurchase Program and Chief Commercialization Officer Departure

According to the filing, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported two significant developments in its November 5, 2026 Form 8-K. On November 2, 2026, the company's Board of Directors authorized the 2026 Repurchase Program, permitting repurchases of up to $1.0 billion of the company's common stock. The filing states that repurchases may be made "from time to time in open market transactions, including pursuant to trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934," in privately negotiated transactions, or by other means, subject to applicable securities laws including Rule 10b-18.

The company disclosed that it anticipates repurchasing approximately $500 million of its common stock under the program by the end of 2026, with the remaining balance during 2027. However, the filing notes that "the timing and amount of any repurchases will depend on a number of factors, including the market price of the Company's common stock, general business and market conditions, the Company's liquidity and capital requirements and other investment opportunities." The program carries no expiration date and imposes no obligation on the company to repurchase any specific dollar amount or number of shares.

Separately, the filing disclosed under Item 5.02 that on November 4, 2026, Alnylam announced Tolga Tanguler's planned departure from his position as Executive Vice President, Chief Commercialization Officer, expected in December 2026. According to the filing, Mr. Tanguler and the company intend to enter into a written agreement no later than his separation date that will contain the terms of his departure. The filing designates statements about the repurchase program and the departure as forward-looking statements subject to the company's cautionary language and risk factors.

What Was Disclosed

Alnylam Pharmaceuticals disclosed a Board-authorized $1.0 billion stock repurchase program with no expiration date and announced that Chief Commercialization Officer Tolga Tanguler will depart in December 2026, with a separation agreement to follow.